Recent studies implicate the immune system and a herpes virus as potential contributors to development of the disease.

Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic ...

When we think about dementia, we often think of a person experiencing memory loss and confusion. While it’s true that these ...

I have a special interest in Alzheimer’s disease. For nearly 25 years, I practiced general neurology in Portland, Oregon, and ...

From the beginning, the approval of its Aduhelm (aducanumab) treatment was met with controversy – over the interactions with the FDA, and the advisor committee’s vote against the treatment ...

INmune Bio's XPro targets neuroinflammation, showing promising biomarker results in Alzheimer's, with a potential to ...

Aduhelm generated hopes in the public and medical community alike when it was developed several years ago under the name aducanumab by Biogen Inc., but disappointing results from initial trials of the ...

The company placed big bets on its Alzheimer’s drug aducanumab which has so far achieved some success. Biogen is now taking the drug to phase 3 trials. Other candidates from big-named ...

Due, in part, to the logical nature of the approach, combination therapy is already widely used in clinical practice. Although compounds with a combined cholinergic–glutamatergic action have ...

随着社会的前进和生活质量的提升，人类的预期寿命在不断增长，老龄化的步伐也在加快，随之而来的是中枢神经系统（CNS）疾病的发病率也在逐步上升，如帕金森病和阿尔兹海默症等老年性疾病对人类的健康和生活质量构成了严重威胁。同时，生活节奏的加快和竞争的加剧带来了更大的精神压力，这导致了失眠和抑郁症等精神障碍的发病率急剧增加。